Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30350420 | 1.00 | KDM1A (0.34) | KDM1AKDM1BALOX15MAPK14CES2 | |
| SCHEMBL7950256 | 0.86 | IDO1 (0.32) | ALOX15 | |
| SCHEMBL919665 | 0.80 | KDM1A (0.42) | KDM1AKDM1BCES2CES1 | |
| SCHEMBL793988 | 0.79 | NMT1 (0.38) | KDM1AKDM1B | |
| SCHEMBL28965365 | 0.79 | ALDH1A1 (0.41) | KDM1AKDM1BALOX15MAPK14 | |
| SCHEMBL6553272 | 0.77 | KDM1A (0.41) | KDM1AKDM1BCES2CES1 | |
| SCHEMBL1806961 | 0.75 | CYP3A4 (0.46) | KDM1AKDM1B | |
| SCHEMBL15287359 | 0.75 | EPAS1 (0.33) | ALOX15 | |
| SCHEMBL21979280 | 0.75 | CA9 (0.36) | ALOX15 | |
| SCHEMBL13550170 | 0.75 | RAPGEF4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092024-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2025-03-20 | — | — | US | disclosed |
| US-20250043059-A1 | POLYURETHANE ADHESIVE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2024175907-A1 | MACROCYCLIC ALPHA4BETA7 INTEGRIN INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2024-08-29 | — | — | WO | disclosed |
| EP-3681928-B1 | PROCESS OF MANUFACTURING POLYOLS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3681928-B1 | PROCESS OF MANUFACTURING POLYOLS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11970574-B2 | Process of manufacturing surfactants and lubricants | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3681931-B1 | PROCESS OF MANUFACTURING SURFACTANTS AND LUBRICANTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3681930-B1 | PROCESS OF MANUFACTURING POLYOLS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11958936-B2 | Process of manufacturing polyols | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-11945808-B2 | Substituted cyclohexyl compounds as NOP inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| US-9216996-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2822954-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| WO-2014100323-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2463276-B1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-2463276-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945808-B2 | Substituted cyclohexyl compounds as NOP inhibitors | OPRL1, OPRK1, NOP56 | KDM1A 4230/4885KDM1B 4674/4885ALOX15 3104/4885 |
| US-11970574-B2 | Process of manufacturing surfactants and lubricants | F12, MSR1, LPAR3 | KDM1A 1772/4885KDM1B 1785/4885ALOX15 1181/4885 |
| US-20250092024-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | KDM1A 4230/4885KDM1B 4674/4885ALOX15 3104/4885 |
| US-20250043059-A1 | POLYURETHANE ADHESIVE | ITGA1, AFF1, PBRM1 | KDM1A 186/4885KDM1B 338/4885ALOX15 1094/4885 |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | KDM1A 1737/4885KDM1B 2042/4885ALOX15 1101/4885 |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | KDM1A 510/4885KDM1B 756/4885ALOX15 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.